Insulin therapy is the only life-saving option for type 1 diabetes (T1D) patients (over 30 million people worldwide). Unfortunately, most T1D patients do not reach the glycaemic targets necessary to prevent the diabetes complications/comorbidities, which continue to exert a high clinical burden and reduced life expectancy of more than 10 years:

Insulin treatment itself is a risk factor:
- Insulin treatment is cause of life-threatening hypoglycemia events (cause of 10% death in T1D)
- Due to its lipogenic action, insulin treatment causes overweight and is understood to be a strong contributing factor to cardiovascular disease (cause of 40% death in T1D).

There is need of a better solution for T1D therapy to:
- Improve glycaemic control
- Lower insulin therapeutic dose

**OUR SOLUTION:** S100A9 – protein based treatment to make insulin therapy in T1D more effective and safer

**Better glycaemic control with less insulin:**

**New mechanism of action:** Metabolic control by activation of TLR4/ mTORC1 signaling axis in hepatic non parenchymal cells (in anti-inflammatory manner)

**COMPETITIVE LANDSCAPE - Insulin adjuvants in T1D**

<table>
<thead>
<tr>
<th>Product</th>
<th>Company</th>
<th>Status</th>
<th>Improved glycemic</th>
<th>Reduced insulin dose</th>
<th>Reduced risk of hypoglycemia</th>
<th>Reduced risk of diabetic ketoacidosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sentin Per</td>
<td>AstraZeneca</td>
<td>Approved only in EU</td>
<td>Yes</td>
<td>Yes</td>
<td>Increased risk</td>
<td></td>
</tr>
<tr>
<td>PAM-10</td>
<td>Sanofi</td>
<td>Approved only in EU for patients with BMI&gt;27</td>
<td>Yes</td>
<td>Yes</td>
<td>Little effect</td>
<td>Increased risk</td>
</tr>
<tr>
<td>S100A9 based Insulin adjuvant</td>
<td>UNIGE spin-off (Diatheris)</td>
<td>Proof-of-concept completed</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Our solution overcomes the major safety limitations of the available adjuvants to insulin therapy for T1D

- Unique selling proposition of our solution: both effective and safe

**CONCLUSION AND PERSPECTIVE**

- We have established a solid PoC in vivo for efficacy and safety with a R&D formulation of the S100A9 protein.
- Next steps of the project:
  - 2023Q3: creation of a Start-up at Geneva (Diatheris SA)
  - 2023Q4: scaling up a GMP compliant S100A9 production
  - 2023Q4: pre-IND meeting
  - 2023Q1: beginning of human trial
  - 2023Q2: Exit. After a Phase 2a we expect opening of opportunity for outsourcing or partnership with pharma.
- A strong support for this game-changing approach has been obtained by recognized International Diabetes Key Opinion Leaders and the translation towards a start-up is backed-up by experienced BioTech Entrepreneurs

**Roadmap**

<table>
<thead>
<tr>
<th>Year</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td></td>
</tr>
<tr>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
</tr>
</tbody>
</table>

- Lead optimization
- Extended PoC
- Preclinical development
- Clinical Phase 1/2a
- Exit

Giorgio Ramadori, giorgio.ramadori@unige.ch

www.diatheris.com